Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CanSino Biologics Inc.
康希諾生物股份公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6185)

VOLUNTARY ANNOUNCEMENT
TD5CP OBTAINS CLINICAL TRIAL APPROVAL IN CHINA FOR PEOPLE AGED 4 TO 5 YEARS OLD

This announcement is made by CanSino Biologics Inc. (the "**Company**") on a voluntary basis.

The Company is pleased to announce that the Tetanus, Reduced Diphtheria and Pertussis (Acellular, Five Components) Combined Vaccine, Adsorbed (the "**Td5cp**") developed by the Company has obtained clinical trial approval granted by the National Medical Products Administration of China to initiate the relevant clinical trial in people aged 4 to 5 years old.

As the incidence and severity of adverse reactions to full-dose co-purified DTaP vaccines tend to increase with both the number of doses administered and the age at vaccination, reduced-dose component-purified Tdap vaccines are generally adopted overseas in place of DTaP vaccines for booster immunization starting at 4 years old. Because of their lower antigen content for pertussis and diphtheria, Tdap vaccines are associated with a lower incidence of adverse reactions.

The clinical trial application proposes to expand the booster vaccination age for Td5cp from 6 years old to 4 to 6 years old, so as to stimulate immune memory and rapidly restore antibody levels to the effective protective range. This would not only help fill the pre-school immunization gap, but also significantly reduce the risk of outbreaks in childcare institutions and primary schools, providing critical support for establishing an all-age immune barrier and controlling the spread of pertussis.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
CanSino Biologics Inc.
Xuefeng YU
Chairman

Hong Kong, November 16, 2026

As of the date of this announcement, the board of directors of the Company comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO and Ms. Jing WANG as executive Directors, Mr. Chi Shing LI as a non-executive Director, and Mr. Yiu Leung Andy CHEUNG, Mr. Man CHO and Ms. Xuefeng JI as independent non-executive Directors.